Winton Group’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.24M | Sell |
2,292
-10,752
| -82% | -$6.06M | 0.04% | 454 |
|
|
2026
Q1 | $7.73M | Buy |
+13,044
| New | +$6.5M | 0.27% | 75 |
|
|
2025
Q4 | – | Sell |
-21,109
| Closed | -$8.85M | – | 1125 |
|
|
2025
Q3 | $8.85M | Buy |
+21,109
| New | +$7.1M | 0.33% | 71 |
|
|
2024
Q1 | – | Sell |
-1,035
| Closed | -$228K | – | 884 |
|
|
2023
Q4 | $228K | Sell |
1,035
-770
| -43% | -$177K | 0.02% | 609 |
|
|
2023
Q3 | $408K | Buy |
1,805
+309
| +21% | +$71.2K | 0.03% | 349 |
|
|
2023
Q2 | $330K | Sell |
1,496
-9,967
| -87% | -$2.21M | 0.03% | 496 |
|
|
2023
Q1 | $2.57M | Sell |
11,463
-1,784
| -13% | -$440K | 0.16% | 155 |
|
|
2022
Q4 | $3.68M | Sell |
13,247
-5,645
| -30% | -$1.43M | 0.24% | 65 |
|
|
2022
Q3 | $3.96M | Buy |
18,892
+817
| +5% | +$183K | 0.26% | 70 |
|
|
2022
Q2 | $4.26M | Buy |
18,075
+2,071
| +13% | +$421K | 0.23% | 90 |
|
|
2022
Q1 | $2.87M | Buy |
16,004
+5,641
| +54% | +$1.07M | 0.15% | 151 |
|
|
2021
Q4 | $2.24M | Buy |
10,363
+1,910
| +23% | +$375K | 0.14% | 190 |
|
|
2021
Q3 | $1.56M | Sell |
8,453
-1,911
| -18% | -$376K | 0.09% | 293 |
|
|
2021
Q2 | $1.86M | Sell |
10,364
-2,975
| -22% | -$567K | 0.1% | 214 |
|
|
2021
Q1 | $2.23M | Sell |
13,339
-822
| -6% | -$137K | 0.13% | 114 |
|
|
2020
Q4 | $2.15M | Sell |
14,161
-24,380
| -63% | -$3.2M | 0.16% | 84 |
|
|
2020
Q3 | $3.89M | Sell |
38,541
-17,331
| -31% | -$1.9M | 0.13% | 217 |
|
|
2020
Q2 | $6.76M | Buy |
55,872
+52,752
| +1,691% | +$5.94M | 0.17% | 117 |
|
|
2020
Q1 | $296K | Buy |
+3,120
| New | +$297K | 0.01% | 1173 |
|
|
2019
Q4 | – | Sell |
-271,159
| Closed | -$21.6M | – | 1773 |
|
|
2019
Q3 | $21.6M | Buy |
271,159
+79,084
| +41% | +$6.37M | 0.26% | 127 |
|
|
2019
Q2 | $15M | Buy |
192,075
+18,559
| +11% | +$1.74M | 0.29% | 138 |
|
|
2019
Q1 | $20.4M | Buy |
173,516
+15,000
| +9% | +$1.75M | 0.41% | 85 |
|
|
2018
Q4 | $17.3M | Buy |
158,516
+66,257
| +72% | +$7.68M | 0.37% | 83 |
|
|
2018
Q3 | $11.8M | Buy |
92,259
+58,814
| +176% | +$7.27M | 0.25% | 164 |
|
|
2018
Q2 | $3.78M | Buy |
+33,445
| New | +$3.68M | 0.1% | 302 |
|
|
2018
Q1 | – | Sell |
-19,091
| Closed | -$2.83M | – | 1168 |
|
|
2017
Q4 | $2.83M | Buy |
+19,091
| New | +$2.43M | 0.08% | 342 |
|
|
2017
Q3 | – | Sell |
-65,741
| Closed | -$8.53M | – | 679 |
|
|
2017
Q2 | $8.53M | Sell |
65,741
-99,994
| -60% | -$12.5M | 0.25% | 122 |
|
|
2017
Q1 | $22.4M | Sell |
165,735
-12,635
| -7% | -$1.91M | 0.61% | 46 |
|
|
2016
Q4 | $25.6M | Sell |
178,370
-79,894
| -31% | -$10.2M | 0.84% | 27 |
|
|
2016
Q3 | $30.5M | Buy |
258,264
+53,415
| +26% | +$6.42M | 0.52% | 62 |
|
|
2016
Q2 | $21.7M | Sell |
204,849
-11,888
| -5% | -$1.33M | 0.36% | 110 |
|
|
2016
Q1 | $24.2M | Buy |
216,737
+59,532
| +38% | +$7.53M | 0.26% | 158 |
|
|
2015
Q4 | $24.6M | Buy |
157,205
+59,369
| +61% | +$8.64M | 0.22% | 177 |
|
|
2015
Q3 | $12.8M | Sell |
97,836
-87,191
| -47% | -$14M | 0.1% | 277 |
|
|
2015
Q2 | $32.2M | Buy |
185,027
+29,040
| +19% | +$5.22M | 0.3% | 122 |
|
|
2015
Q1 | $26.9M | Buy |
155,987
+57,115
| +58% | +$8.71M | 0.21% | 181 |
|
|
2014
Q4 | $12.8M | Sell |
98,872
-375,234
| -79% | -$48.4M | 0.16% | 223 |
|
|
2014
Q3 | $61M | Sell |
474,106
-166,914
| -26% | -$17.2M | 0.44% | 64 |
|
|
2014
Q2 | $56.7M | Buy |
+641,020
| New | +$61.6M | 0.39% | 78 |
|
Other funds holding UTHR
ACA
JT
Winton Group's UTHR Position: Q2 2026 in Review
Winton Group reduced its United Therapeutics (UTHR) stake by 82% in Q2 2026, selling an estimated $6.06M and leaving 2,292 shares worth $1.24M. The position accounts for 0.04% of the portfolio, ranked #454.
Winton Group first reported a position in UTHR in Q2 2014 and has held it in 39 quarters since. The position peaked at $61M in Q3 2014. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- Winton Group held 2,292 shares of United Therapeutics worth $1.24M as of Q2 2026.
- Winton Group sold 10,752 United Therapeutics shares in Q2 2026, an estimated $6.06M.
- United Therapeutics made up 0.04% of Winton Group's portfolio in Q2 2026, its #454 holding.
- Winton Group first reported a position in United Therapeutics in Q2 2014 and has held it in 39 quarters since.
- Winton Group's United Therapeutics position peaked at $61M in Q3 2014.
- 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.